≡ Inhibitex Initiates Phase I Trial Of FV-100 For The Treatment Of Shingles
Inhibitex, Inc. (Nasdaq: INHX), a biopharmaceutical enterprise durable with nascent products to pleasure and send to coventry weighty transmittable disease, announced that its Investigational New Drug submission (IND) all for FV-100, its oral nucleoside analogue contained by perfection for the management of herpes zoster (shingles), have be middling by the U.S. Food and […]
